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STREPTOCOCCAL SORE THROAT AND RHEUMATIC FEVER
William C. Giauque, D. B.
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Thomas C. Peebles, M.D.
I. Introduction
Analysis of medical problems is, in general,
complicated by both the need to consider multiple objective
criteria and the need to allow for uncertainty in diagnostic
and treatment procedures. A general methodology for defining
objective functions valid under uncertainty exists in the
fcrm of von Neumann - Morgenstern utility theory. Recent
theoretical developments relating to the formulation and
assessment of multidimensional utility functions offer a
practical technique useful for multiple criteria. Some uses
of these techniques have appeared in the applications
literature, including some descriptions of medical
applications. Generally, however, these applications
utilize assumptions leading to the additive form of the
utility function, thus avoiding a number of assessment
problems inherent in more complicated forms. In this paper,
we describe the analysis of a medical problem of
considerable interest, the prevention and treatment of
rheumatic fever. In this work, the assumptions leading to
the additive form of the utility function were not
justified, but it was possible to utilize a less restrictive
form, the multiplicative form. Techniques for assessing the
parameters of this form are described, and some general
comments concerning the usefulness of such techniques in
medical problems are made. A more complete discussion of
this work can be found in Giauque 10 .
II. The Medical Problem
Rheumatic fever and associated rheumatic heart disease
remain significant health problems in the United States
today, despite the existence of effective medical means of
preventing the disease. In 1968 about 16,000 deaths from
this disease were reported in the United States, a rate far
exceeding annual death rates from poliomyelitis (2893 in
1952) and measles (364 in 1963) in the years preceeding the
massive immunization efforts against these diseases 20 . In
1970, it was estimated that about 100,000 new cases of
rheumatic fever and rheumatic heart disease occur each
year 29 .
Rheumatic fever is closely associated with
streptococcal infections, generally of the upper respiratory
tract. "Strep throat", as most parents of school age
children know, is one of the most common diseases of
childhood, accounting for more child-hours lost from school
than any other acute bacterial illness 20 . Streptococcal
infections themselves can be acute, resulting in
considerable discomfort and, if untreated, requiring about
five days of bed rest, or can be so mild that the patient
doesn't realize he is infected. Treatment usually gives
almost immediate relief from disease symptoms20 . In most
cases a child with a strep infection recovers completely,
but in a small percentage of cases rheumatic fever, or even
more rarely a kidney disease known as acute
glomerulonephritis, develops. Both of these diseases can
result in long term disability and/or death.
Streptococcal infections are relatively easy to treat,
as streptococci are extremely sensitive to penicillin and
related antibiotics. A ten day course of oral penicillin or
a single injection of the drug is generally sufficient to
eradicate the infection. Rheumatic fever, on the other
hand, is poorly understood and difficult or impossible to
treat. Generally a rheumatic patient is given an antibiotic
(usually penicillin) to eradicate any strep infections which
may be present and put to bed for a period of time lasting
up to three months (more in some cases) . There is some
evidence that treatment with salicylates or steroids may
shorten or alleviate the course of the disease, but the
effectiveness of such treatments is controversial, and at
best is limited 17 . Acute glomerulonephritis is likewise an
extremely difficult disease to treat.
A number of studies have shown that successful
eradication or prevention of strep infections significantly
lower occurrence rates of both rheumatic fever and acute
1,21
glomerulonephritis . Thus, it appears that a major
barrier to lowering the incidence of these diseases is the
lack of a method of determining when antistreptocbccal
treatment is warranted. This raises a number of the
guestions which were addressed in this study. First, a
number of strep infections never become acute, thus are not
brought to the attention of the medical community. Is it
worth conducting community-wide surveys of school children
to detect such cases? Is it worth checking all members of a
strep patients family to isolate additional strep
infections? Secondly, when a child develops an acute sore
throat, it is by no means certain that it is caused by
streptococci, as a number of viral infections can cause
similar symptoms. Penicillin is ineffective against viral
infections. The primary clinical tool available in
differentiating these agents is the throat culture, but
results of this test are not available for at least
twenty-four hours. Thus, when confronted with an acute sore
throat, a clinician has at least two decisions to make: (1)
should he take a throat culture or not; and (2) should
antibiotic treatment of the illness be delayed until the
results of the throat culture become known? In this latter
decision, one must weigh the relative risk of starting
antibiotic treatment early and perhaps uselessly versus the
risk of delaying treatment at least 24 hours to be sure of
the diagnosis, thus adding to the danger of contracting
rheumatic fever or nephritis. Finally, there has been some
controversy in the medical literature over the propriety of
maintaining former rheumatic patients on a continuous
program of penicillin medication for life, as is normally
recommended.
III. Analytical Approach
A. Specification of the Result Vector
In investigating the questions outlined above, it
became clear that any final measure of outcome would have to
include a number of factors affecting the patient. For
example, the decision to begin antibiotic treatment affects
not only the risk of rheumatic fever and the danger of an
antibiotic reaction, but the length and severity of the sore
throat and the cost of the treatment. A list of all factors
considered important in this problem is given in Table I.
The dimensionality of this result vector was first reduced
as much as possible by simple trade-off arguments. For
example, a measure of total dollar cost to the patient was
derived by summing all the patients direct and indirect
costs. It was assumed that the exact allocation of these
costs among the various uses was much less important than
the total of all the costs. After these simplifications,
the result vector contained ten dimensions summarized in
table II. It was now necessary to define a utility function
over this multidimensional result space.
TABLE I. COMPLETE VECTOR OF RESULTS
I. Factors Related to Dollar Costs
A. Direct cost of the treatment to the practice
B. Amount of doctors time used
1. Direct cost
2. Opportunity cost
C. Amount of nurses' time used
1. Direct cost
2. Opportunity cost
D. Estimated overhead expense of the practice allocated
to the case
E. Amount billed to the patient
1. Amount paid out-of-pocket by the patient
2. Amount paid by insurance or welfare plans
F. Costs not billed to the patient by government,
insurance, or welfare plans
G. Amount of parent's and patient's time used
1. Direct cost (lost wages or profits,
babysitting fees, etc.)
2. Opportunity cost
H. Patient's other expenses as a result of treatment
1. Medical (prescriptions, supplies, etc.)
2. Nonmedical (transportation, etc.)
II. Factors Related to Health
A. Immunity developed to one strain of strep
(yes or no)




C. Method of receiving medication
1. Single injection







6 - 25. All combinations of initial occurrences
described by 2-5 plus second occurrences
described by 1-5.
E. Acute rheumatic fever episode
1. Severe
2. Mild
F. Prophylactic regimen for rheumatic fever patients
1. Episodal - treat each strep recurrence
a. Single injections
b. Pills three times per day for ten days
G. Long term rheumatic fever effects










TAELE II. CONSOLIDATED VECTOR OF RESULTS
Dimension Description
x Cost to the patient
1
x Cost (or profit) to the doctor
2
x Cost to the public or insurance system
3
x Method of medication if any (oral
A
•r injected)
x Immunity developed to infecting strain of
strep - yes er ne)




x Severity of acute rheumatic fever episode
a
x Type of post rheumatic medication, if any
9
x Long term effects of rheumatic fever
10
B. Specification of the Utility Function
For any but the most trivial cases, direct assessment
of a general multidimensional utility function is out of the
question. Humans are poor at making trade-offs in
multidimensional spaces and tend to rely on lexicographic
procedures, thus making a direct assessment suspect. In
addition, the sheer number of judgments which would have to
be elicited to define a general utility function over more
than two, or perhaps three, dimensions would make this
approach impractical. These problems could be simplified if
one could represent a multidimensional utility function as a
function of many unidimensional functions. Symbolically,
one would like to write
u (x) = f [ u (x ) , u (x ) , . . . , u (x ) ] (1)1122 n n
where x = (x ,x , ... , x ) is a particular consequence from
1 2 n
consequence space X. = X .X X , u(x) is the
1 2 n
utility of x, and the u (x ) are the utilities of each of
i i
the x . Each unidimensional function u (x ) could be
i i i
assessed separately by standard techniques, and assuminq
that the functional form of (1) were known, complete
assessment of u (x) would be possible.
There are a number of structural assumptions which lead
to such a representation. Three assumptions investigated in
the course of this research are utility independence,
pairwise preferential independence, and pairwise
12,13,14,15
marqinality, as defined by Keeney . These terms
are defined and the resultinq functional forms summarized
here for convenience. A more extensive discussion of these
concepts can be found in the references discussed in the
Note at the end of this paper.
III.B.1. Utility Independence
One speaks of one particular dimension of a conseguence
space, say dimension x , as being utility independent of the
i
remaining dimensions if the decision maker's utility curve
over x is the same (within a positive linear
i
transformation) for all values of the remaining dimensions.
Formally stated, define X = X . X X .X
""i- - 1 2 i-1 i + 1
... . X t and let x be a member of X . Then X is
n """i- i- i
utility independent of X if one's preference order over
i-
lotteries on X with X held fixed does not depend on the
i i-
fixed amount x If X is utility independent of X for
"~i- i i-
i = 1, 2, ... , n then order one mutual utility independence
is said to hold. In this case, Keeney 15 shows that (1)
takes a guasi-additive form
Mx) = z" k.u. (*.) (2)i=1 li i
n n
+ 2 y k u (x ) u (x )i=1 3=i+1 ij i i j J
n n n
+ 5 5 y k u (x ) u (x ) u (x )
1 = 1 3=1+1 Tc=3 + 1 13k 1133k k
+ ...




Although this result allows a representation such as
(1), the number of constants which must be assessed in (2)
is excessively large for many practical problems. If n = 6,
for example, one would have to evaluate 41 constants. More
useful is the result summarized below.
III.B.2. Pairwise Preferential Independence
Pairwise preferential independence is said to hold if
the trade-offs one is willing to make between attributes
taken two at a time are not dependent on the values of the
remaining attributes. Formally stated, define X = X ...
ij- ~ 1
• A • A •••••A • A •••••A fQ.il(lX6iX
i-1 i+1 j-1 j+1 n ij-
be a particular value from X . Then X . X is pairwise
ij- i J
preferentially independent of X if one's preference order
ij-
for conseguences (x , x ,x ) with x held fixed does not
i j ij- ij-
depend on the fixed amount x . Keeney 14 then shows that
ij-
u (x) can be represented by one of the following forms:
n
u (x) = "5 k u (x ) (additive form), or (3)
1=1 i i i
n
1 + ku (x) = JT [ 1 + kk u (x ) ] (multiplicative
1=1 i i i
form)
, (4)
where k and the k are constants with 0<k <1 and k>-1 . In
i i
both these cases the assessment requirements are reasonable
even for conseguence spaces of fairly high dimensionality.
The additive and multiplicative cases can be distinguished
on the basis of the following property.
III.B.3. Pairwise Marginality
If the decision maker's preferences for gambles depends
only on the marginal distributions of the consequences,
rather than the joint distributions, then the additive form
3,5,6,7,8,22
of the utility function (4) holds . A convenient
test for this property is the pairwise marginality test.
Let x l , x 2 , x l , and x 2 be distinct values of x and x , and
i i J J i J
let x take on some constant value. Define gambles A and
ij"
B as follow:
gamble A yields (x l ,x 1 ,x ) with prob .5
i j ij-
and (x 2 ,x 2 ,x ) with prob. .5; and
i j ij-
gamfcle B yields (x l ,x 2 ,x ) with prob. .5,
i j ij-
and (x 2 ,x 1 ,x ) with prob. .5 .
i j ij-
If the decision maker is indifferent to the gambles, then
pairwise marginality holds between attributes x and x . If
i j
pairwise marginality holds between all i and j, then (3)
holds.
III.C. Utility structure Verification
To illustrate the verification of utility independence,
consider the dimension "days ill with strep infection". The
maximum and minimum number of days possible were determined
to be ten and zero, respectively. Utility independence was
verified by the following kinds of questions:
"Suppose values of all other dimensions are
specified (ie. the cost to the patient, doctor, and
insurance systems, immunity developed, method of
medication, severity of antibiotic reaction, etc. are
10
all given). Now consider the gamble
no days ill with prob. p f
ten days ill with prob. 1-p
and determine a number x such that if you had to choose
either the gamble or the x days ill for sure, you would
be indifferent. Now suppose a different set of values
for the other dimensions is given and ycu are presented
with the same gamble and asked to assess x again. Does
the value of x change?"
If the value of x doesn't change no matter what values are
given for the other dimensions, and if this is true for all
gambles on the "days ill" dimension, then the "days ill"
attribute is utility independent of the other attributes.
Utility independence of the remaining dimensions can be
similarily verified.
To illustrate the verification of preferential
independence, consider the dimensions "cost to the patient"
and "days ill with strep infection". In verifying
preferential independence, we are attempting to determine
whether or not we need to consider values of the remaining
attributes when making trade-offs between cost to the
patient and days ill. The following dialogue illustrates
this process.
"Consider a conseguence, which we'll call conseguence A
for convenience, involving
($100 cost to the patient, 5 days ill with strep
infection, and some previously specified values
for all the other attributes)
.
Now determine a dollar figure x such that consequence
B, defined as
($x cost to the patient, no days ill with strep
infection, and same values for other attributes as
consequence A)
is exactly as attractive as consequence A. Now change
the values of some or all of the attributes other than
11
cost and days ill. Does the value of x change?"
If the value of x doesn't change for all values of the other
attributes, and if this holds true for all trade-offs
between dollars and days ill, then these two attributes are
preferentially independent of the other attributes.
Preferential independence between other pairs of attributes
is determined in a similar manner.
In the strep - rheumatic fever problem, both utility
independence and preferential independence were verified
over the entire attribute space. The property of pairwise
marginality was not, however, found to hold between all
pairs of attributes. For example, the gambles A and B
below, involving combinations of "antibiotic reaction" and
"long term effects of rheumatic fever" were not, in general,
egually preferred.
Gamble A: (no reaction, no long term effects) with
prob. .5 ; and
(severe reaction, severe rheumatic damage) with
prob. .5 .
Gamble B: (no reaction, severe rheumatic damage) with
prob .5 ;
and (severe reaction, no long term effects) with
prob. .5 .
Pairwise marginality was found to hold only if the two
attributes involved were attributes x (cost to the
patient) , x (cost or profit to the doctor) , x (cost to the
2 3
public or insurance system) , and x (method of medication)
.
These results, together with the utility independence and
preferential independence properties already verified, imply
the following form of the utility function:
u (x) = k u (x ) + k u (x ) + k u (x )^ 111 222 333
k u (x ) + k u (x ) , (5)**4 r r r
12
where
X. = <X , X , X , X , X - X ) ,
j; 56789 10
and
1 + ku(x ) = [1+kk u (x ) ] [1+kk u (x ) ] .
r 555 101010
Again, k and the k are constants with k > -1 and 0<k <1 , i
i i
= 1, , 10 .
IV. Assessment of the Parameters of the Utility Function
In general if the additive form of the utility function
holds for a result vector of dimensionality n, the constants
in (3) can be evaluated by choosing n linearly independent
n
values x 1 , ... , x of the result vector and directly
i
assessing the utilities u ( x ) for i = 1 , ... , n . One thus
obtaines d linearly independent eguations in the unknown k
,
i
and the values of the constants are readily obtained. The
i
values of x. used in this determination must be carefully
chosen, however, as it is difficult to assess a consistent
utility measure over multidimensional consequences. A
useful scheme is as follows. Let x° represent some
3
c
natural "base" level of dimension x , and let x
J i
represent some value of x different from x° . Define
i i
i c
x = (xo, . . . , x° , x , xo , . . . , x° ) and assess
1 i-1# i i+1 n
i
u (x ) . This enables the decision maker to concentrate on
i
one dimension at a time in assessing the u (x )
13
*Particularly useful schemes involve setting x° = x (or x )
J J* J
c * *
and x = x (or x ) , where x and x represent the most
i i i* j j*
and least desirable outcomes of consequence j . The
unidimensional utility functions u (x ) are generally scaled
j J
*
so that u (x ) = 1 and u (x ) = .
j j j j*
In the multiplicative case the same ideas apply, except
that n+1 parameters must be estimated. If one can set x°
j
c *
equal to x and x equal to x , as discussed above, values
j* i i
of the constants are easily obtained since a series of n
equations of the form
i
1 + ku(x ) = 1 + kk
i
result, so the k are determined immediately. The value of
i
k can then be obtained from the consistency equation
1 + k = IT" ( 1 + kk ) ,
1=1 i
* *
which results when x = (x , . . . , x ) .
1 n
In some situations the above procedure may be difficult
to apply. In medical problems, for example, many of the x
i
could represent dimensions describing health, so the x *s
i*
would represent various extremes of ill health. In order to
c
assess u(x , ... , x, ... , x ) one would have to
x* i n *
11*
consider his preferences under the assumption that his
health was at the worst possible state in all attributes but
one, a procedure which involves obvious difficulties. It
would be more natural in this case to assess utilities of
* * c *
the form u(x ,x # ... ,x , ... ,x ) , corresponding tc the12 i n
case where the patient is in perfect health along all
dimensions but one. In order to recover the scaling
parameters under this scheme, one must solve a series of n+1
nonlinear eguations in n+1 unknowns. It can be shown that
there is exactly one solution to these equations which
yields scaling parameters in the feasible range. Furthur,
a simple search procedure which locates that solution can be
defined. A proof of these statements can be found in the
Appendix.
IV. Results
The unidimensional utility functions and scaling
parameters necessary to specify the utility function for
this problem were determined, through interviews, for two
doctors, three nurse - practitioners (nurses specially
trained to handle a variety of routine diagnostic and
therapeutic situations), three public health officials, and
five patients. We were interested not only in answering the
medical questions raised in this research but in determining
the stability of the medical recommendations resulting from
the utility assessments, and in investigating systematic
differences in the utilities of members of the different
assessing groups, particularly if those differences affected
recommended treatments. Optimal decisions were obtained for
each of the respondants by using each assessed utility
function as the objective criterion in a dynamic programming
15
algorithm.
It was found that there was almost total agreement
among respondents on the proper course of medical care
implied by the utility functions, although the assessed
utility functions differed consideraoly. We also found that
within the detection limits dictated by our small sample
size, there were no systematic differences in the utilities
assessed by the different groups. Differences of individual
utilities within groups were much larger than differences
among groups.
The model strongly indicated that oral penicillin
therapy should be started immediately if there were the
slightest suspicion of strep infection. Throat cultures
should be taken on all patients, even if the perceived risk
of strep infection was small, and if the culture results
proved negative, therapy should be discontinued on those
patients on antibiotics. It was also shown that routine
community-wide streptococcal screenings should be performed.
Once a patient has rheumatic fever, current medical practice
indicates that he should be kept under continual penicillin
(or other antibiotic) medication, and the model results
confirmed the propriety of this practice, at least until the
patient reaches twenty-one years of age. The age of the
patient when the initial strep infection is suspected and
the length of time he waits to see the doctor after becoming
ill have no effect on any of these recommendations.
Finally, the relative effectiveness of a physician was
compared to that of a nurse - practitioner in the diagnosis
and care of strep infections, with the result that the nurse
was shown to be at least as effective as the physician.
V. Conclusion and Implications
16
Decision problems in medicine have become increasingly
complex and important in recent years, both because of
rapidly expanding knowledge and technology, and higher
stakes in terms of money and human life. The modern medical
doctor has more tools at his disposal in combating illness
than at any time in history, but often the knowledge of how
the tools can best be used is lacking. The sheer volume of
new medical knowledge makes it difficult to integrate the
knowledge into a consistent system for treating illness
which is in some sense optimal, and communicating the system
to practicing medical personnel. In addition, the
traditional organization of medical knowledge along the
lines of specific diseases, their symptoms, and their
treatments makes it difficult to integrate new techniques
which may affect differential diagnosis or recommended
treatments for a number of diseases.
The analysis outlined in this paper demonstrates the
usefulness of the multidimensional utility approach to
defining objective functions in situations of this
complexity. In combination with the other tools of decision
analysis, this forms a powerful, flexible method of analysis
allowing systematic inclusion of new knowledge in the canon
of accepted medical practice. The complexity and time
demands of the analysis probably preclude patient-by-patient
analysis, but the methods offer great promise in determining
recommended practices for dealing with entire groups of
patients with specific groups of symptoms. There is some
evidence that protocols can be developed for many disease
systems which are structured enough for unskilled personnel
to apply in routine medical examinations. Another use of
this analytical technique is suggest by Forst 9 , who offers
the interesting idea of using a decision analytic approach
to determine malpractice settlements. A multidimensional
utility objective would, in general, be necessary in such an
approach. Finally, the means offered of trading off many
17
conflicting factors and evaluating the utility of
combinations of factors may offer a workable scheme for
defining a guality of care measure.
18
Note:
References <4, 11, 16, 24, 25, and 27 discuss the basic
theory of utility functions, with particular emphasis on
application methodology for unidimensional utility
functions. The concept of risk aversion, particularly
important in utility functions over monitary consequences,
is discussed and developed in references 2 and 23.
Assessment procedures to insure certain desirable properties
are discussed in references 19, 24, 25, and 28. Reference
26 discusses assessment procedures and application
methodologies. A number of the results cited in the paper
also appear in various forms in references 3, 5 # 6, 7, 8,
18, and 22.
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APPENDIX - DETERMINATION OF THE ROOTS OF THE PARAMETER
EQUATIONS
Consider the general assessment scheme where n+1
D D ID ID
vectors x = (x,...,x) are chosen and u (x ) assessed
1 n
for each m=1 , 2,. .
.
,n+1 . The n+1 equations
m n m
1 + ku(x ) = XT [ 1 + kk u (x ) ]
3=1 3 3 3*
contain the information necessary to solve tor the
m
parameters k and k , i=1,...,n if the x are independent.
i
ra
The equations can be simplified if the x are chosen such
that
mi c
x = x = (x°, ... , x° , x , x° , ... , x° )
1 i~1 i i + 1 n
for m=1
,
. . . n and
n + 1
x = x° = (xo, , x° )
1 n
where the xo represent arbitrary but "natural" base levels
3
c
and x # x° . One then obtains one equation of the form
i i
n
1 + ku{x0) = XT [ 1 + kk u (x ) ] (6)
3=1 J 3 3
and n equations of the formin
1 + ku(x ) = A JT [ 1 + kk u (x ) ] , i=1,...n (7)
i 3=1 3 3 3
where
c
A = [1+kk u (x ) ] / [1+kk u (xo) ]
i i i i i i i
20
Substituting equation (6) for the multiplicative term in (7)
gives
i
H-ku(x ) = A . (1+ku (x.°) ) (8)
i
which can be solved for k , giving
i
i
u (x ) - u (xO)
k. =
. . I - (9)
l
c c i
u (x ) - u (XO) + k[u (x )u(xO) - u (xO)u(x )]ii ii ii ii
th
Substituting this result into (6) gives the n order
equation in k
n
1 + ku(xO) = JJ1=1
[ u (x ) - u (xO) ] . [ 1 + ku(xO) ]
i i i i
_, _ ____
^
[u (x ) - U (XO) ] + k[ u (x )u(xQ) - U (XO)U(X ) ]ii ii ii ii
(10)
* c
If we let x° = x and x = x and scale the utility
i i i i*
functions so that u (x ) = 1 and u (x ) =0, then (10)




1 + k = . (11)




It can be shown that there is exactly one value of k greater
than -1 sucn that equality holds. This result is put in the




The motivation and outline of this proof are due to
21
Professor Richard F. Meyer of the Harvard Business School.
There is exactly one root k of (11) greater than -1 .
Furthur, the root lies in (-1,0) or (0,inf) depending on
n i








/ T"L [1 - *. + zv. ] . (12)i=1 l l




TT (1+za.) = z IT (1 + a.) (13)
1=1 l 1=1 l
and define the function
n (n-1) n
f(z) = TT, (1*za.) - z TT„ (1+a.) . (14)1=1 l 1=1 l
We now wish to know how many solutions z>0 exist such that
f (z) equals zero.
First note that one solution occurs at z=1. This is
a degenerate case corresponding to k=0, in which case the
utility function is additive. In the following, it will be
assumed that z*1. Also note that f (0) and f(inf) are
both positive since the a are positive if the v are
i i
restricted to (0,1). Thus one of the two cases illustrated
in Figure 1 must exist, depending on the slope of f (z) at
z=1. This slope is given by
22
Figure 1 - Shape of f (z)
Case a: f'(l) greater than sero
f(»)
Odd ne. ef reets helew one, sere er even ne. of roots above one
Case »: f'(l) less than sere
f(»)
Sven no. or sere roots ftelow one, odd no. of roots above one
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f'(2) = TT" (1 + za.) 5
D
[a./(1*za.) ]1=1 -) i=1 1 1
(n-2) n
-(n-1)z fT (1+a.) , (15)
i=1 l
which gives, when evaluated at z=1,
f (1) = TL (1 + a.)[ 7
n
a./(1 + a.) ]
3 = 1 3 1=1 l l
- (n-1) TT (1+a.)
i=1 l
= TT ( 1 + a .)CZ
n
v. - (n-1) ] . (16)
3=1 3 1=1 l
The sign of f
•
(1) depends only on the sign of the term in
the brackets. A physical interpretation for this quantity
is discussed after the proof of the theorem is concluded.
If equation (14) is expanded and like terms in a
i
collected, we derive
n n-1 n-2 n-1
f(z) = A (z -z ) A (z -z ) +
o 1
n-1 n-1
+ A (z-z ) + (1-z ) , (17)
n-2
where A through A are positive. Letting y = 1/z,
o n-2
n
substituting in (17) and multiplying by y gives
n n-1
f (y) = (y -y) + a (y -y) + ...
n-2
A (yz-y) + A (1-y) . (18)
1 o
The second derivitive of f (y) is given by
f"(y) = n(n-1)y + (n-1) (n-2) y" A
n-2
... + 2A (19)
which is positive for all y>0. Thus f(y) is convex for
y>0 and can be zero at most twice. One zero is at y=1 r
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as mentioned above, and the other zero must lie in (0,1) or
(1,inf) if f
' (y) at y=1 is greater than or less than
zero, respectively. Since y=1/z, if f (y) =0 in (0,1)
then f (z) must be zero in (1,inf). The condition for
f(y)=0 in (0,1) is that f • (y) evaluated at y= 1 be
greater than zero, so that f (z) evaluated at z=1 is
less than zero. The opposite statements hold true if
f(y)=0 holds for 1<y<inf. Since k=z-1, the theorem
follows immediately.
These results allow a relatively simple determination
of the value of k. The value of f • (z) at z=1 can be
computed frcm eguation (15), then a search made over the
appropriate range using (14) as a guide tc convergence.
Convergence can be accelerated by using (15) and exploiting
the convexity property of f (z) as well.
n
The value of the term > v ~( n ~ 1 ) appearing in
i=1 i
eguation (16) can be interpreted as an expression of
multivariate attitude towards risk. Suppose, for example,
n








implying that the decision maker would prefer a gamble with
i
a 1/n chance at each v = u (x ), i=1,2...,n to a gamble
i
*
with a 1/n chance at x and a (n-1)/n chance at x ,
*
where u (x ) =0 and u (x )=1. The decision maker then
25
1
prefers getting one of the x. for sure rather than taking
a risk of 1/n of having the "catastrophic" outcome x
occur; in the unidimensional case, this behavior is
characterized as risk averse.
It would be misleading, however, to characterize the
decision maker as either risk averse or risk seeking on the
basis of his attitudes toward the gamble described in (20)
.
An individual may be risk averse in the usual sense along
each of the dimensions of his utility vector when considered
singly, yet still show raultiattribute "risk seeking"
behavior in that he may prefer the right side of equation
(20) to the left. In medical problems, two dimensions may
both represent serious health consequences, and the decision
maker may well prefer a chance of having both together and a
complementary chance of having reither over a certainty of
having one of them. For example, it is perfectly reasonable
to prefer the gamble A
(1 year in bed, 5 years from life) with prob.5 or
(no years in bed, no years from life) with prob. .5
to the gamble B
(1 year in bed, no years from life) with prob. .5, or
(no years in bed, 5 years from life) with prob. .5
although the decision maker may be risk averse along both
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